Asia Green Biotechnology

Asia Green Biotechnology Current Liabilities

Delisted·Sep 23, 2026

The Current Liabilities of Asia Green Biotechnology (ASIA.CN) as of Nov 15, 2026 is 527,333.00 CAD. In the previous year, Current Liabilities was 253,690.00 CAD — a change of 107.87% (higher).

Current Liabilities

527,333.00CAD

YoY

107.87%

Last updated:

Current Liabilities of Asia Green Biotechnology is 2023 527,333.00 CAD. Current Liabilities of Asia Green Biotechnology was 2022 253,690.00 CAD. It decreases by 107.87% higher compared to the previous year.

The Asia Green Biotechnology Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
130,007.00 CAD
Jan 1, 2019
42,407.00 CAD
Jan 1, 2020
26,229.00 CAD
Jan 1, 2021
41,097.00 CAD
Jan 1, 2022
253,690.00 CAD
Jan 1, 2023
527,333.00 CAD
The Asia Green Biotechnology Current Liabilities history
YEARCurrent LiabilitiesYoY
527,333.00CAD+107.87%
253,690.00CAD+517.30%
41,097.00CAD+56.69%
26,229.00CAD-38.15%
42,407.00CAD-67.38%
130,007.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Asia Green Biotechnology Stock analysis

What does Asia Green Biotechnology do? Asia Green Biotechnology Corp develops and supplies proprietary organic hybridization technology for agri-technology applications. The company partners with InPlanta Biotechnology Inc. for hemp cultivation under a license agreement, and collaborates with Swysh Inc. and Pathway Rx Corp for cannabinoid extract development. Revenue is generated through the supply of technology and related products, with operations expanding in Cambodia and Thailand through R&D programs. The firm focuses on commercial hemp and cannabinoid product development under licensed agreements. The company's primary market segments include agricultural technology providers and medicinal cannabinoid extract buyers. InPlanta Biotechnology Inc. licenses hemp cultivation, while Swysh Inc. and Pathway Rx Corp. license cannabinoid extract development. Asia Green Biotechnology Corp. supplies technology and manages the commercialization of these products derived from its organic hybridization technology. Asia Green Biotechnology Corp. operates under license agreements with InPlanta Biotechnology Inc., Swysh Inc., and Pathway Rx Corp. to develop and supply hemp and cannabinoid products. The company's revenue streams come from technology supply and product commercialization under these agreements, with R&D programs in Cambodia and Thailand supporting future market expansion. Asia Green Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Asia Green Biotechnology stock

Current Liabilities of Asia Green Biotechnology is 527,333.00 CAD in 2023.

Current Liabilities of Asia Green Biotechnology changed from 253,690.00 CAD to 527,333.00 CAD, representing a 107.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Asia Green Biotechnology since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Asia Green Biotechnology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Asia Green Biotechnology

All Key Metrics — Asia Green Biotechnology